WAVE.V (MCap 4 Mil) 2x BIG Cancer Drug targeting almost $2 BILLION Market are close to US & Europe approval /its a covid 19 gem too /COMPLETELY unknown stock = This could be a 20 ,30 BAGGER or even more ... Waverley Pharma (WAVE.V) Market Cap CAD$ 4 million Price 0.08 https://www.waverleypharma.com/generic-product-pipeline.html WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications. Currently there is no marketed generic version for this product in the United States, and the brand generates yearly revenue of over $1 billion USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe WAV-102 is an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. Currently there is no marketed generic for this product and the brand generates yearly revenue of over $800 million USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe. Waverley Pharma Announces Collaboration withDr. David E. Herbert and the University of Manitoba forthe Development of a Synthetic Library of Chloroquine Analogsto Treat COVID-19 https://www.waverleypharma.com/uplo...u_of_m_collaboration__25_june_2020__final.pdf
Any trading platforms available in Canada with the same pre and post trading hours as in the USA? Or which place is the best in regards to most hours being available pre and post on the NASDAQ, NYSE and ASE?
FANTASTIC News .... Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries https://www.newswire.ca/news-releas...in-multiple-european-countries-856239417.html
2 Blockbuster Drugs with US and European approval expected during THIS quarter , market cap of laughable C$ 9 million is more than a PURE GIFT . This UNknown stock could run toward $5 in the coming months Share Price: 0.15 Waverley Pharma Announces Signing of Term Sheet to Acquire Exclusive Rights to Market Six Generic Oncology Products in the United States https://finance.yahoo.com/news/electric-royalties-closes-acquisition-bissett-114500612.html The brands represented by these six generic products, referred to by the Company as WAV-103, WAV-104, WAV-105, WAV-106, WAV-107 and WAV-108, had combined sales of more than $3 billion USD in 2019.
